Skip to search formSkip to main contentSkip to account menu

galantamine hydrobromide

Known as: Benzofuro(4,3,2-efg)(2)benzazocin-6-ol, 1,2,3,4,6,7,7a,11c-octahydro-9-methoxy-2-methyl-, Hydrobromide, Lycoremine Hydrobromide, Galanthamine Hydrobromide [Chemical/Ingredient] 
The hydrobromide salt form of galantamine, a tertiary alkaloid obtained synthetically or naturally from the bulbs and flowers of Narcissus and… 
National Institutes of Health

Related topics

Related topics

11 relations
24 HR galantamine hydrobromide 16 MG Extended Release Oral Capsule [Razadyne]24 HR galantamine hydrobromide 8 MG Extended Release Oral CapsuleAlzheimer's DiseaseGalantamine

Narrower (2)

NivalineRazadyne

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations
Abstract Galantamine hydrobromide, a promising acetylcholinesterase inhibitor is reported to be associated with cholinergic side… 
Highly Cited
2012
Highly Cited
2012
Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes.
2010
2010
Probing Torpedo californica acetylcholinesterase catalytic gorge with two novel bis-functional galanthamine derivatives.
N-Piperidinopropyl-galanthamine (2) and N-saccharinohexyl-galanthamine (3) were used to investigate interaction sites along the… 
Highly Cited
2008
Highly Cited
2008
A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease
Objective: To study the efficacy and safety of galantamine hydrobromide ER for the enhancement of cognition in non-demented… 
Highly Cited
2008
Highly Cited
2008
N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum.
Review
2006
Review
2006
Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
Galantamine hydrobromide is a tertiary alkaloid drug that has been developed and approved in a number of countries including the… 
Review
2005
Review
2005
Cholinesterase Inhibitors in the Treatment of Dementia
Abstract Dementia associated with probable Alzheimer's disease (AD) is one of the most common types of dementia. Patients with AD… 
Highly Cited
2004
Highly Cited
2004
The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
BACKGROUND Alzheimer disease (AD) causes progressive cognitive and functional decline over years. Although cholinesterase… 
Highly Cited
2004
Highly Cited
2004
Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial.
CONTEXT There is no established pharmacological treatment for the core symptoms of chronic fatigue syndrome (CFS). Galantamine… 
Highly Cited
1996
Highly Cited
1996
Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
Acetylcholinesterase (AChE) inhibitors from several chemical classes have been tested for the symptomatic treatment of Alzheimer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)